Purpura Thrombocytopenic Thrombohemolytic

Thrombocytopenic thrombohemolytic purpura: understanding, diagnosis and treatment

Introduction:
Thrombocytopenic thrombohemolytic purpura (eng. purpura thrombocytopenica thrombohaemolytica) is a rare and serious disease that is characterized by thrombocytopenia (decrease in the number of platelets in the blood), hemolytic anemia (destruction of red blood cells) and thrombosis in the microvasculature. In this article, we will review the basic aspects of thrombocytopenic thrombohemolytic purpura, including its causes, diagnosis, and treatments.

Causes:
Thrombocytopenic thrombohemolytic purpura is usually associated with impaired immune system function and autoimmune reactions. In most cases, it is caused by antibodies called antiplatelet antibodies, which destroy platelets and activate the coagulation system, leading to thrombosis. However, the exact mechanisms of this disease are not fully understood.

Diagnostics:
Diagnosis of thrombocytopenic thrombohemolytic purpura can be difficult because its symptoms may overlap with other diseases. Main signs include purpura (bleeding into the skin, mucous membranes and organs), thrombocytopenia (low platelet count) and hemolytic anemia (increased destruction of red blood cells). A blood test for antiplatelet antibodies and an assessment of kidney function may be required to confirm the diagnosis.

Treatment:
Treatment of thrombocytopenic thrombohemolytic purpura includes several approaches. One of the main methods is plasmapheresis, in which part of the patient's blood with antiplatelet antibodies is removed and then returned back. This helps reduce the amount of antibodies in the blood and improve the patient's condition. Immunotherapy, corticosteroids and immunoglobulins are also used to suppress the immune system and prevent platelet destruction.

Forecast:
The prognosis for patients with thrombocytopenic thrombohemolytic purpura may vary. In some cases the disease may be mild and respond well to treatment, while in other patients it may be severe and progressive. Platelet levels and renal function status are important prognostic factors. In some cases, a kidney transplant may be required.

Conclusion:
Thrombocytopenic thrombohemolytic purpura poses a serious health threat and can be severe. Correct diagnosis, timely treatment and monitoring can improve the prognosis and quality of life of patients. Further research and development of new therapeutic approaches will help expand our knowledge of this disease and improve treatment outcomes.

However, it is important to note that this article is not medical advice and you should consult with a qualified healthcare professional before making any decisions about the diagnosis, treatment or management of thrombocytopenic thrombohemolytic purpura.

Thrombocytopenia purpurea and thrombohemolysis purpura thrombohemolysis First attack of thrombocytopenia purpurea With repeated attacks of purpurea, thrombocytopenia purpura occurs, which is manifested by subcutaneous hemorrhage. An increase in the volume of these hemorrhages can be caused by the fragility of small vessels in the tissues, which contributes to their noticeable expansion (the appearance of a hematoma).

Purpuria could be a congenital abnormality. But this was only a rare violation. Pathology becomes obvious either during puberty or some time after its end. Often the disease is diagnosed in older people. The size of the hematoma and the presence or absence of indirect symptoms may indicate the causes of the problem.

In any case, purpuria worsens a person’s quality of life. For this reason, he is forced to consult doctors. When determining the causes, it is important for doctors